Full Press Release Details
Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis.
BIIB
Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis
Key Takeaway: Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis